Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Expert Analyses of the following article:

AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes

Source: www.fiercebiotech.com
May 30, 2008
AGI-1067 May Address More than the Blood Sugar
Author: GLG Expert Contributor
This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome. 
Eric GruffApril 16, 2008
AtheroGenics' AGI-1067 Shows Some Promise, But There Are Still Questions
Author: Eric Gruff, PhD MBA, Principal, E4 Consulting
The 3-month reduction in HbA1c demonstrated by AGI-1067 is promising, but I still have many questions regarding the design and outcomes. There are many existing therapies that lower A1c - many have undesireable side effects like weight gain or hepatotoxicity.

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747